The antiviral medication, remdesivir, remains effective against Omicron subvariants, including XBB. However, no monoclonal antibodies (eg, casirivimab-imdevimab, tixagevimab-cilgavimab, sotrovimab, bebtelovimab) are effective against Omicron subvariants XBB. As of August 5, 2023, XBB variants accounted for almost 80% of cases in the United States. The EG.5 variant has increased and accounts for 17% of cases.
Learn more about remdesivir.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Mary L. Windle. Rapid Rx Quiz: COVID-19 Treatment Updates - Medscape - Aug 22, 2023.